Fiduciary Trust Co. continued to hold its stake in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,407 shares of the medical instruments supplier’s stock at the end of the first quarter. Fiduciary Trust Co. owned approximately 0.08% of LeMaitre Vascular worth $355,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Conestoga Capital Advisors LLC purchased a new stake in shares of LeMaitre Vascular during the first quarter valued at about $9,549,000. Summit Creek Advisors LLC purchased a new stake in shares of LeMaitre Vascular during the first quarter valued at about $5,311,000. Columbia Wanger Asset Management LLC increased its stake in shares of LeMaitre Vascular by 21.0% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,093,903 shares of the medical instruments supplier’s stock valued at $26,943,000 after buying an additional 189,608 shares during the last quarter. Thomson Horstmann & Bryant Inc. increased its stake in shares of LeMaitre Vascular by 111.3% in the first quarter. Thomson Horstmann & Bryant Inc. now owns 359,339 shares of the medical instruments supplier’s stock valued at $8,850,000 after buying an additional 189,280 shares during the last quarter. Finally, Perkins Capital Management Inc. purchased a new stake in shares of LeMaitre Vascular during the first quarter valued at about $2,677,000. 66.33% of the stock is owned by institutional investors and hedge funds.
Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) traded up 2.07% during trading on Tuesday, hitting $28.55. 275,910 shares of the stock were exchanged. The stock’s 50 day moving average price is $30.30 and its 200-day moving average price is $25.59. The company has a market cap of $537.00 million, a price-to-earnings ratio of 47.66 and a beta of 0.65. LeMaitre Vascular Inc has a one year low of $13.52 and a one year high of $33.22.
LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, May 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.03. The company had revenue of $24.10 million for the quarter, compared to analyst estimates of $23.48 million. LeMaitre Vascular had a net margin of 13.34% and a return on equity of 14.42%. The firm’s revenue was up 18.7% compared to the same quarter last year. On average, analysts predict that LeMaitre Vascular Inc will post $0.70 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 8th. Stockholders of record on Wednesday, May 24th were issued a $0.055 dividend. The ex-dividend date of this dividend was Monday, May 22nd. This represents a $0.22 annualized dividend and a dividend yield of 0.77%. LeMaitre Vascular’s dividend payout ratio is currently 36.67%.
WARNING: “LeMaitre Vascular Inc (LMAT) Position Held by Fiduciary Trust Co.” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/06/20/lemaitre-vascular-inc-lmat-position-held-by-fiduciary-trust-co.html.
Several analysts have issued reports on LMAT shares. First Analysis started coverage on shares of LeMaitre Vascular in a research note on Tuesday, March 21st. They issued an “overweight” rating and a $29.00 price objective for the company. Canaccord Genuity reissued a “buy” rating and issued a $28.00 price objective on shares of LeMaitre Vascular in a research note on Thursday, April 27th. Stifel Nicolaus raised their price objective on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 22nd. Finally, Craig Hallum started coverage on shares of LeMaitre Vascular in a research note on Tuesday, June 6th. They issued a “hold” rating and a $31.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $27.00.
In other news, Chairman George W. Lemaitre sold 87,342 shares of the company’s stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $32.35, for a total value of $2,825,513.70. Following the transaction, the chairman now directly owns 3,484,149 shares in the company, valued at approximately $112,712,220.15. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 9,102 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $31.12, for a total transaction of $283,254.24. Following the completion of the transaction, the chief executive officer now owns 3,450,815 shares in the company, valued at $107,389,362.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 317,805 shares of company stock worth $9,910,332. Company insiders own 23.70% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc and related companies with MarketBeat.com's FREE daily email newsletter.